Evidence map›Paper›PMID 34049783›Full record

ArticleUrologic oncology2021

Can quantitative analysis of multi-parametric MRI independently predict failure of focal salvage HIFU therapy in men with radio-recurrent prostate cancer?

Arnas Rakauskas, Taimur T Shah, Max Peters, Jagpal S Randeva, Feargus Hosking-Jervis, Michael J Schmainda, Clement Orczyck, Mark Emberton, Manit Arya, Caroline Moore and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Urologic oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Quantitative Prostate MRI, From theAJR. American journal of roentgenology · 2025
    Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 4 countries.

Arnas RakauskasImperial Prostate, Division of Surgery, Department of Surgery and Cancer, Imperial College, London, UK. Electronic address: Rakauskas.arn@gmail.com.
Taimur T ShahImperial Prostate, Division of Surgery, Department of Surgery and Cancer, Imperial College, London, UK.
Max PetersDepartment of Radiotherapy, University Medical Center Utrecht, Heidelberglaan, Utrecht, The Netherlands.
Jagpal S RandevaImperial Prostate, Division of Surgery, Department of Surgery and Cancer, Imperial College, London, UK.
Feargus Hosking-JervisImperial Prostate, Division of Surgery, Department of Surgery and Cancer, Imperial College, London, UK.
Michael J SchmaindaImaging Biometrics, LLC, Wisconsin, USA.
Clement OrczyckDepartment of Urology, University College London Hospitals NHS Foundation Trust, London, UK.
Mark EmbertonDepartment of Urology, University College London Hospitals NHS Foundation Trust, London, UK.
Manit AryaDepartment of Urology, University College London Hospitals NHS Foundation Trust, London, UK.
Caroline MooreDepartment of Urology, University College London Hospitals NHS Foundation Trust, London, UK.
Hashim U AhmedImperial Prostate, Division of Surgery, Department of Surgery and Cancer, Imperial College, London, UK.
Imperial College London · GBUniversity College London Hospitals NHS Foundation Trust · GBImaging Biometrics (United States) · USUniversity College London · GBUniversity Hospital Heidelberg · DE

Funding

Wellcome Trust 204998/Z/16/Z
6 · The paper itself

Abstract

objectivesFocal salvage HIFU is a feasible therapeutic option in some men who have recurrence after primary radiotherapy for prostate cancer. We aimed to determine if multi-parametric quantitative parameters, in addition to clinical factors, might have a role in independently predicting focal salvage HIFU outcomes.

methodsA retrospective registry analysis included 150 consecutive men who underwent focal salvage HIFU (Sonablate500) (2006-2015); 89 had mpMRI available. Metastatic disease was excluded by nodal assessment on pelvic MRI, a radioisotope bone-scan and/or choline or FDG PET/CT scan. All men had mpMRI and either transperineal template prostate mapping biopsy or targeted and systematic TRUS-biopsy. mpMRI included T2-weighted, diffusion-weighted and dynamic contrast-enhancement. Pre-HIFU quantitative mpMRI data was obtained using Horos DICOM Viewer v3.3.5 for general MRI parameters and IB DCE v2.0 plug-in. Progression-free survival (PFS) was defined by biochemical failure and/or positive localized or distant imaging results and/or positive biopsy and/or systemic therapy and/or metastases/prostate cancer-specific death. Potential predictors of PFS were analyzed by univariable and multivariable Cox-regression.

resultsMedian age at focal salvage HIFU was 71 years (interquartile range [IQR] 65-74.5) and median PSA pre-focal salvage treatment was 5.8ng/ml (3.8-8). Median follow-up was 35 months (23-47) and median time to failure was 15 months (7.8-24.3). D-Amico low, intermediate and high-risk disease was present in 1% (1/89), 40% (36/89) and 43% (38/89) prior to focal salvage HIFU (16% missing data). 56% (50/89) failed by the composite outcome. A total of 22 factors were evaluated on univariable and 8 factors on multivariable analysis. The following quantitative parameters were included: Ktrans, Kep, Ve, Vp, IS, rTTP and TTP. On univariable analysis, PSA, prostate volume at time of radiotherapy failure and Ve (median) value were predictors for failure. Ve represents extracellular fraction of the whole tissue volume. On multivariable analysis, only Ve (median) value remained as an independent predictor.

conclusionsOne pharmacokinetic quantitative parameter based on DCE sequences seems to independently predict failure following focal salvage HIFU for radio-recurrent prostate cancer. This likely relates to the tumor microenvironment producing heat-sinks which counter the heating effect of HIFU. Further validation in larger datasets and evaluating mechanisms to reduce heat-sinks are required.

Indexed as

AgedHumansMaleMultiparametric Magnetic Resonance ImagingProstatic NeoplasmsRetrospective StudiesSalvage TherapyHIFUProstate cancerQuantitative parametersRadiotherapySalvage treatment

Identifiers

PMID34049783
PMCPMC8639607
OpenAlexW3165341661

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.